MetaCap

Agios Pharmaceuticals (AGIO) vs Braveheart Bio (BRVE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Braveheart Bio is the larger company by market cap ($1.67 billion vs $1.65 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AGIO-13.62%BRVE-31.58%
+22%-11%-45%
Aug 6, 20261 yearNov 20, 2026
AGIO-14.47%BRVE-32.03%
+17%-12%-41%
Aug 3, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AGIO versus BRVE key metrics
MetricAGIOBRVE
Share price$27.60$20.39
Market cap$1.65B$1.67B
1-day change-4.03%+5.81%
YTD return+1.40%—
1-year return+9.35%—
5-year return-24.28%—
EPS (TTM)$-6.31$-6.59
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$54.03M—
Revenue growth (YoY)+48.03%—
Net income (latest FY)$-412.78M—
Gross margin88.26%—
Operating margin-873.87%—
Net margin-764.01%—
52-week high$44.09$32.00
52-week low$24.16$16.70
Distance from 52-week high-37.40%-36.28%
Analyst consensusbuystrong_buy
Avg. price target upside+67.07%+123.15%
Average volume1.06M491.27K
Shares outstanding59.81M82.07M
Employees53949
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Agios Pharmaceuticals

AGIO stock →

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.

Health Care · Biotechnology: Pharmaceutical Preparations · 539 employees

About Braveheart Bio

BRVE stock →

Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees

AGIO vs BRVE FAQ

Which is bigger, Agios Pharmaceuticals or Braveheart Bio?

Braveheart Bio (BRVE) is larger, with a market capitalization of $1.67B compared with $1.65B for Agios Pharmaceuticals (AGIO).

Are Agios Pharmaceuticals and Braveheart Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons